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Background and aim: Creating potential clinical markers for risk assessment in patients with COVID-19 continues to be an area of
interest. In this study, we aimed to evaluate whether serum albumin level and thrombocyte/lymphocyte ratio are related to the severity
of the disease.
Materials and methods: The patients were divided into two groups according to the severity of disease. Demographic data, serum albumin
value, lymphocyte count, TLO-1 values (thrombocyte/lymphocyte ratio-1), the highest thrombocyte count during hospitalization,
TLO-2 (thrombocyte/lymphocyte ratio-2) values formed by the highest thrombocyte count, were recorded.
Results: There was no statistically significant differences (P > 0.05) in terms of sex, thrombocyte count at the time of admission, and
highest thrombocyte count during hospital follow-up. There were statistically significant differences in terms of age, comorbidity,
lymphocyte value at the time of hospitalization, lymphocyte count during hospital follow-up, TLO 1, TLO 2, and serum albumin values
between the groups. The ICU group were found to be older, had higher rates of comorbidity, lower lymphocyte values, higher TLO 1-2,
and lower serum albumin levels (P < 0.05).
Conclusion: TLO-2 ratio above 260 and lymphocyte level below 1 103 cells/µL, would be a predictor of further intensive care unit need.
Key words: Severity of COVID 19, platelet lenfosit ratio, serum albumin value

1. Introduction
The COVID-19 disease was seen to start with the occurrence
of idiopathic pneumonia cases in China in December 2019
[1,2].1 At the end of 2019 in Wuhan, China, the COVID-19
virus spread rapidly all over China and then to many parts of
the world [3]. The COVID-19 cases in many countries apart
from China, where the first epidemic started, were observed
due to the spread and severity of the virus. Therefore, The
COVID-19 was defined as a global epidemic (pandemic)
on March 11, 2020.2 While clinical signs of fever, weakness,
cough, and shortness of breath can be observed in the
patients, laboratory findings may be normal, as well as

decreased leukocyte count, decreased lymphocyte count,
thrombocytopenia, increased transaminases, increased
lactate dehydrogenase (LDH), and creatine kinasemyoglobin elevation [4]. However, not much is known
about clinical markers for risk of worse prognosis in patients
with COVID-19. Currently, there is no specific treatment
for COVID-19. Therefore, the evaluation of disease severity,
course, and prognosis becomes increasingly important [5].
In this study, we aimed to evaluate whether serum
albumin level, thrombocyte count, lymphocyte count and
thrombocyte/lymphocyte ratio were related to the severity
of the disease.

World Health Organization (2020). Novel Coronavirus – China [online]. Website http://www.who.int/csr/don/12-january2020-novelcoronavirus-china/en/ [accesed 20 January 2020].
1
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2. Materials and methods
Our study was a retrospective study and was planned on
patients with positive COVID-19 PCR tests who applied
to our hospital on March, April, May 2020. The study was
conducted after the approval of the Gülhane Education
and Research Hospital Ethics Committee, with project
number 2020-10. The laboratory tests of 63 patients with
positive COVID-19 PCR test, 33 being followed in the
intensive care unit, and 30 patients in the inpatient unit
of the Gülhane Education and Research Hospital, were
scanned through the hospital automation system. Signs
of COVID-19 infection may be dyspnea and respiratory
distress. Patients with a respiratory rate > 30 /min, PaO2 /
FiO2 < 300, SpO2 < 90, or PaO2 < 70 despite 5 L/m oxygen
therapy were evaluated in terms of intensive care admission in the common routine practice of our hospital. We
formed 2 groups according to the severity of disease; those
who were followed up in the intensive care unit (severe
COVID-19 patients), and those deemed appropriate for
follow-up in the inpatient unit (moderate and mild COVID-19 patients). Patients under 18 years of age, patients
with chronic liver failure, hematological malignancy or
chronic hematological disease (immune thrombocytopenic purpura, paroxysmal nocturnal hemoglobinuria,
thrombotic thrombocytopenic purpura, aplastic anemia,
immune or nonimmune secondary thrombocytopenia before COVID-19), malignancy diseases with nonremission
status, and patients who were receiving chemotherapy and
radiotherapy were not included in the study.
The demographic data, comorbidities, and laboratory
values of 63 patients who met the inclusion criteria were
recorded. Peripheral blood samples of the patients were
analyzed as a conventional medical approach at admission and during hospitalization. Demographic data, serum albumin value during hospitalization, lymphocyte
count, TLO-1 values (thrombocyte/lymphocyte ratio-1),
the highest thrombocyte count during hospitalization, the
highest thrombocyte count, and TLO-2 values (thrombocyte/lymphocyte ratio-2) formed by the highest thrombocyte count was recorded. TLO-1 and TLO-2 values were
calculated by using laboratory data. The Apache scores of
the patients followed in the intensive care unit were recorded. The relationship between independent variables
and the severity of COVID-19 disease was investigated.
All statistical analysis was performed using IBM
SPSS version 25.0 (IBM Corp., Armonk, NY, USA)
and MedCalc 15.8 (MedCalc Software Ltd, Ostend,
Belgium) statistical package programs. While evaluating
the study data, besides descriptive statistical methods (frequency, percentage, mean, standard deviation, median,
min-max), the chi-square test was also used to compare
qualitative data. The compliance of the data to normal
distribution was evaluated by Kolmogorov–Smirnov and
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Shapiro–Wilk tests. In the study, Independent samples ttest was used for intergroup comparisons of normally distributed data, paired samples t-test for comparing repetitive measurements, Mann–Whitney U test for intergroup
comparisons of nonnormally distributed data, and Wilcoxon signed ranks test for comparing repetitive measurements. The ROC curve (receiver operating characteristic)
method was used to determine the distinctiveness of the
variables. Correlations between variables were evaluated
using the Pearson correlation test.
3. Results
A total of 63 patients (30 COVID intensive care unit
patients, and 33 COVID-1 inpatient unit patients) were
included in the study. The patients included in the study
were 29 females and 34 males. The average age of the
patients with positive COVID-19 who were followed up
was 53 years (Table 1).
When both groups (inpatient unit and ICU unit) were
compared; there was no statistically significant differences
(P > 0.05) in terms of sex, thrombocyte I (thrombocyte
count at the time of admission), and thrombocyte II
(highest thrombocyte count during hospital followup). At the same time, there were statistically significant
differences in terms of age, comorbidity, lymphocyte
I (lymphocyte value at the time of hospitalization),
lymphocyte II (lymphocyte count during hospital followup), TLO 1 (thrombocyte/lymphocyte ratio at the time of
hospital admission), TLO 2 (highest thrombocyte during
hospital follow-up), and serum albumin values between
the groups (Table 2).
Patients followed up in the ICU (severe COVID-19
patients) were found to be older, had higher rates of
comorbidity, lower lymphocyte I and II values, higher
TLO 1-2, and lower serum albumin levels (P < 0.05)
(Figures 1–5).
When the patients were evaluated in terms of
thrombocyte, lymphocyte, and TLO values within groups;
Table 1. Characteristics of the patients.
n = 63
Group
Sex

%

Inpatient unit 33

52.4

ICU

30

47.6

Female

29

46.0

Male

34

54.0

Age (year)*

53.4 ± 19.4 53.0 (18.0–88.0)

Comorbidities No

33

52.4

Yes

30

47.6

*: mean ± SD/median (min-max).
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Table 2. Comparisons between groups.

Sex1
Age (year)2

Female

Inpatient unit ICU
(n = 33)
(n = 30)
15 (45.5%)
14 (46.7%)

Male

18 (54.5%)

16 (53.3%)

General 40.5 ± 13.5

67.6 ± 14.4

0.000 b

Female

36.5 ± 1.5

67.1 ± 16.0

0.000 b

Male

43.9 ± 10.9

67.9 ± 13.3

0.000 b

P

0.117 b

0.883 b

24 (72.7%)

9 (30.0%)

Comorbidities 1 No

P
1.000 a

P

9 (27.3%)
195.0
(155.5–220.5)
221.0
(195.5–297.0)
0.000 d

0.002 a
21 (70.0%)
189.5
0.836 c
(152.3–246.3)
307.5
0.070 c
(223.0–374.3)
0.000d

I

1.4 ± 0.5

1.1 ± 0.7

0.012 b

II

1.6 ± 0.5

1.2 ± 0.8

0.013 b

P

0.005 e
159.0
(115.0–205.5)
170.0
(122.8–232.0)
0.323 d

0.386 e
229.0
0.014 c
(151.5–309.3)
329.5
0.000 c
(178.0–598.3)
0.002 d

Albumin 2

4.0 ± 0.3

3.1 ± 0.3

0.000 b

Apache

--

40.1 ± 16.7

--

Yes
Thrombocytes 3 I
II
Lymphocytes

TLO 3

3

I
II
P
2

1

: n (%), 2: mean ± SD, 3: median (IQR), a: chi-square test, b:
independent samples t test, c: Mann-Whitney U test, d: Wilcoxon
signed ranks test, e: Paired samples t test.

there was a statistically significant difference between
thrombocyte 1 and 2 values in both ICU and inpatient
unit patients (P < 0.05). It was found that the values at the
second measurement time were higher in both groups. In
lymphocyte values, there was no statistically significant
difference between the first and second measurement
values of patients in the ICU group (P > 0.05). At the same
time, it was found that there was a statistically significant
difference between the first and second measurement
values of patients in the inpatient unit (P < 0.05), and
the values at the second measurement time were high. In
TLO values, there was no statistically significant difference
between the first and second measurement values of
patients in the inpatient unit group (P > 0.05). At the same
time, it was found that there was a statistically significant
difference between the first and second measurement
values of patients in ICU (P < 0.05), and the values at the
second measurement time were high.

When serum albumin level and thrombocyte/
lymphocyte ratios were evaluated with acute physiology
and chronic health evaluation II (APACHE II) of patients
admitted to intensive care due to severe COVID-19
disease; it was found that there was a positive correlation
between TLO-2 values and apache values at the level of r
= 0.450 and this relationship was statistically significant
(P < 0.05). (Figure 6).
It was found that the relationship between serum
albumin during ICU and APACHE values at ICU
admission was not statistically significant (P > 0.05)
(Table 3). As a result of the evaluations made with the
ROC analysis, when the service-ICU groups were
compared in terms of the need for intensive care followup; age values > 54 were found to be the cut-off point
(AUC = 0.906, P = < 0.0001, 95% CI: 0.806 to 0.965). It
was found that 1 103 cells /µL was the cut-off point in
lymphocyte-1 values (AUC = 0.684, P = 0.0084, 95% CI:
0.554–0.795). It was found that ≤ 1 103 cells/µL was the
cut-off point in lymphocyte-2 values (AUC = 0.683, P
= 0.009, 95% CI: 0.553–0.794). It was found that > 221
was the cut-off point in TLO-1 values (AUC = 0.681, P =
0.0101, 95% CI: 0.551–0.793). TLO-2 values > 260 were
found to be the cut-off point (AUC = 0.762, P = 0.0001,
95% CI: 0.638–0.860). It was found that 3.6 g/dL was the
cut-off point for albumin values (AUC = 0.989, P = <
0.0001, 95% CI: 0.924–1.000) (Table 4, Figure 7).
4. Discussion
There is currently no specific treatment for COVID-19.
Therefore, evaluation of the severity of disease and
prognosis becomes increasingly essential [5]. Plebani
et al. stated that laboratory data could play an essential
role in the early detection, diagnosis, and management
of many diseases [6]. Thrombocytes have important
roles in coagulation and inflammatory pathways.
Impairments in their number and functionality may
closely be related to various diseases [7,8]. Thrombocytes
are produced by megakaryocytes in the bone marrow.
Such as inflammation: IL-6 can stimulate the formation
of megakaryocytes by increasing the level of TPO [9,10].
In their analysis of 138 patients, Wang D et al. found that
the total number of white blood cells in the peripheral
blood of these patients was normal or decreased in the
early stage of the disease, and the number of lymphocytes
also decreased [11]. In our study, when both groups were
compared in terms of lymphocyte values, it was found
that lymphocyte values in patients following the intensive
care unit were lower than those followed in the inpatient
unit.
In a retrospective study of 30 patients, Rong Qu et al.
showed that the lymphocyte level at the first admission
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Figure 1. In-group and between-group comparisons/age.

Figure 2. In-group and intergroup comparisons/comorbidities.

Figure 3. In-group and intergroup comparisons/lymphocyte-1 and 2.
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Figure 4. In-group and intergroup comparisons/TLO-1 and TLO-2.

Figure 5. In-group and intergroup comparisons-serum albumin value.

to the hospital was closely related to the prognosis. In
our study, it was found that the lymphocyte II values of
the patients who were followed up in the inpatient unit
were higher than the patients followed in the intensive
care unit due to severe COVID-19 disease. (P < 0.05).
In addition, in the study of Rong Qu et al., patients with
high TLO values during the treatment of COVID-19 had
a long hospital stay, and severe pneumonia was developed
in these patients [12]. As a result of evaluation with ROC
analysis, they determined the TLO cut-off point as 126.7
and the sensitivity as 100%, and the specificity as 86%.
In our study, we found that TLO-2 cut-off point was >
260, sensitivity 90%, and specificity 63.3% (P < 0.001). In
addition, in our study, there was no statistically significant
difference (P > 0.05) in TLO values between the first
and second measurements in the inpatient unit group.

In contrast, there was a statistically significant difference
between the first and second measurement values in the
ICU group (P < 0.05). The second measurement values
were found to be higher.
It was found that there was a positive correlation
between TLO-2 values and acute physiology and chronic
health evaluation II (APACHE II) values at the level of r
= 0.450, and this relationship was statistically significant
(P < 0.05). When this situation is evaluated in terms of
mortality and morbidity for patients who need intensive
care follow-up, TLO-2 values give clinicians a meaningful
idea about the disease’s course and prognosis during their
follow-up.
Huang et al. evaluated the data of 36 patients who died due
to COVID-19 in 2020 and reported that 80.65% of patients
had hypoalbuminemia and 70.59% lymphopenia [13].
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Figure 6. Relations with Apache–TLO-2.
Table 3. Relations with Apache.
Apache
r

P*

Albumin

–0.130

0.494

TLO-1

0.149

0.432

TLO-2

0.450

0.013

* Pearson correlation test.

Table 4. Recommended cut-off values for important parameters in inpatient-ICU hospitalization.
AUC

Cut-off

Sensitivity

Specificity

%95 GA

P*

Age

0.906

>54

80.0

90.9

0.806–0.965

<0.001

Lymphocyte-1

0.684

≤1

63.3

72.7

0.554–0.795

0.008

Lymphocyte-2

0.683

≤1

50.0

87.9

0.553–0.794

0.009

TLO-1

0.681

>221

56.7

81.8

0.551–0.793

0.010

TLO-2

0.762

>260

63.3

90.9

0.638–0.860

<0.001

Albumin

0.989

≤3.6

96.7

93.9

0.924–1.000

<0.001

*ROC curve.

Albumin is a protein synthesized by the liver that plays
an important role in maintaining nutrition and plasma
osmolarity [14]. Juyi Yi et al. stated that low levels of
albumin were an indicator of poor nutritional status of
the patient and this condition also decreased the body’s
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immunity, and the host’s immune response to RNA virus
infection was often weakened by nutritional deficiencies
that could be ignored during clinical diagnosis and
treatment [15]. In this study, Juyi Yi et al. determined
the cut-off point of serum albumin level in confirmed
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Figure 7. Recommended cut-off values for important parameters in inpatient group - ICU hospitalization.

COVID-19 critically ill patients as 3.51 g/dL (sensitivity:
76.47%; specificity: 73.81%) [15]. Similarly, in our study,
we determined the cut-off point of serum albumin value
in critically ill patients as ≤ 3.6 g/dL. (sensitivity: 96.7;
specificity: 93.9).
Liu Y. et al. noted that the most common laboratory
abnormalities were hypoalbuminemia, lymphopenia,
decreased lymphocyte and neutrophil percentage, high
C-reactive protein (CRP), high lactate dehydrogenase
(LDH), and decreased CD8 count. They also found
that serum albumin value, lymphocyte cell count and

percentage, neutrophil percentage, lactate dehydrogenase,
and CRP levels were highly correlated with acute lung
injury [16]. This situation could be critical in the patient
group with severe COVID-19 disease.
Liu W. et al. examined 78 patients with COVID-19 PCR
+. They found that serum albumin level was significantly
lower in the clinically progressed patient group compared
to the clinically stable patient group (36.62 ± 6.60, 41.27 ±
4.55 g/dL, U = 2.843, P = 0.006) [17]. In our study, we also
found low serum albumin levels in patients with severe
COVID-19 (3.1 ± 0.2, 4.0 ± 0.3 g/dL, P = 0.000).
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5. Conclusion
The TLO-2 ratio above 260, the lymphocyte level below 1
103 cells/µL, and the albumin value below 3.6 g/dL would
be a predictor of further intensive care unit need and might
suggest that the patient’s clinic would be severe. Patients
with these laboratory values should be followed closely
and acted upon quickly during the treatment process.
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